Bezlotoxumab + Standard CDI treatment
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Trial Timeline
Feb 12, 2020 → Feb 22, 2023
NCT ID
NCT04317963About Bezlotoxumab + Standard CDI treatment
Bezlotoxumab + Standard CDI treatment is a pre-clinical stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04317963. Target conditions include Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04317963 | Pre-clinical | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection